{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T08:50:20Z","timestamp":1772787020532,"version":"3.50.1"},"reference-count":85,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["2020.10231.BD"],"award-info":[{"award-number":["2020.10231.BD"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1007\/s40264-024-01470-0","type":"journal-article","created":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T17:02:16Z","timestamp":1724086936000},"page":"1203-1224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["A Comparison of Active Pharmacovigilance Strategies Used to Monitor Adverse Events to Antiviral Agents: A Systematic Review"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6517-6021","authenticated-orcid":false,"given":"Renato","family":"Ferreira-da-Silva","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0314-8233","authenticated-orcid":false,"given":"Joana","family":"Reis-Pardal","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8759-1486","authenticated-orcid":false,"given":"Manuela","family":"Pinto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4586-2910","authenticated-orcid":false,"given":"Matilde","family":"Monteiro-Soares","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1277-3401","authenticated-orcid":false,"given":"Bernardo","family":"Sousa-Pinto","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-0613","authenticated-orcid":false,"given":"Manuela","family":"Morato","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0133-7217","authenticated-orcid":false,"given":"Jorge Junqueira","family":"Pol\u00f3nia","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-8158","authenticated-orcid":false,"given":"In\u00eas","family":"Ribeiro-Vaz","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,8,19]]},"reference":[{"issue":"22","key":"1470_CR1","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMp0706892","volume":"357","author":"J Avorn","year":"2007","unstructured":"Avorn J. In defense of pharmacoepidemiology\u2014embracing the yin and yang of drug research. N Engl J Med. 2007;357(22):2219\u201321. https:\/\/doi.org\/10.1056\/NEJMp0706892.","journal-title":"N Engl J Med"},{"key":"1470_CR2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1136\/bmj.b1025","volume":"338","author":"S Garattini","year":"2009","unstructured":"Garattini S, Chalmers I. Patients and the public deserve big changes in evaluation of drugs. BMJ. 2009;338:1025. https:\/\/doi.org\/10.1136\/bmj.b1025.","journal-title":"BMJ"},{"key":"1470_CR3","doi-asserted-by":"publisher","first-page":"204209862093859","DOI":"10.1177\/2042098620938595","volume":"11","author":"M Alomar","year":"2020","unstructured":"Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Ther Adv Drug Saf. 2020;11:2042098620938595. https:\/\/doi.org\/10.1177\/2042098620938595.","journal-title":"Ther Adv Drug Saf."},{"key":"1470_CR4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3389\/fmed.2019.00147","volume":"6","author":"C Torre","year":"2019","unstructured":"Torre C, Cary M, Borges FC, et al. Intensive monitoring studies for assessing medicines: a systematic review. Front Med (Lausanne). 2019;6:147. https:\/\/doi.org\/10.3389\/fmed.2019.00147.","journal-title":"Front Med (Lausanne)."},{"issue":"1","key":"1470_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s40360-017-0186-x","volume":"18","author":"AO V\u00e1zquez-Alvarez","year":"2017","unstructured":"V\u00e1zquez-Alvarez AO, Brennan-Bourdon LM, Rinc\u00f3n-S\u00e1nchez AR, Islas-Carbajal MC, Huerta-Olvera SG. Improved drug safety through intensive pharmacovigilance in hospitalized pediatric patients. BMC Pharmacol Toxicol. 2017;18(1):79. https:\/\/doi.org\/10.1186\/s40360-017-0186-x.","journal-title":"BMC Pharmacol Toxicol"},{"key":"1470_CR6","unstructured":"Agency EM. ICH Topic E 2 E Pharmacovigilance Planning (Pvp). 2005. CPMP\/ICH\/5716\/03. June 2005. https:\/\/www.ema.europa.eu\/en\/ich-e2e-pharmacovigilance-planning-pvp-scientific-guideline"},{"issue":"1","key":"1470_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1517\/14740338.2012.629184","volume":"11","author":"L H\u00e4rmark","year":"2012","unstructured":"H\u00e4rmark L, van Grootheest K. Web-based intensive monitoring: from passive to active drug surveillance. Expert Opin Drug Saf. 2012;11(1):45\u201351. https:\/\/doi.org\/10.1517\/14740338.2012.629184.","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"1470_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1136\/jamia.1998.0050305","volume":"5","author":"AK Jha","year":"1998","unstructured":"Jha AK, Kuperman GJ, Teich JM, et al. Identifying adverse drug events: development of a computer-based monitor and comparison with chart review and stimulated voluntary report. J Am Med Inform Assoc. 1998;5(3):305\u201314. https:\/\/doi.org\/10.1136\/jamia.1998.0050305.","journal-title":"J Am Med Inform Assoc"},{"key":"1470_CR9","doi-asserted-by":"crossref","unstructured":"Bansal A, Agrawal AK, Sharma L, Jain S. A comparative study of active and passive adverse drug reaction reporting systems in terms of false reporting rate. 2020.","DOI":"10.5937\/scriptamed51-29065"},{"key":"1470_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3390\/cells10051263","volume":"10","author":"AO Otto","year":"2021","unstructured":"Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of contemporary antiretroviral drugs: a review and evaluation of published clinical data. Cells. 2021;10:5. https:\/\/doi.org\/10.3390\/cells10051263.","journal-title":"Cells"},{"issue":"1","key":"1470_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s12098-021-04045-4","volume":"90","author":"S Ray","year":"2023","unstructured":"Ray S, Seth A, Singh S, et al. Short-term adverse drug reactions to antiretroviral therapy in children with HIV: a cohort study. Indian J Pediatr. 2023;90(1):9\u201315. https:\/\/doi.org\/10.1007\/s12098-021-04045-4.","journal-title":"Indian J Pediatr"},{"issue":"9","key":"1470_CR12","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/pds.4022","volume":"25","author":"M Mann","year":"2016","unstructured":"Mann M, Mengistu A, Gaeseb J, et al. Sentinel site active surveillance of safety of first-line antiretroviral medicines in Namibia. Pharmacoepidemiol Drug Saf. 2016;25(9):1052\u201360. https:\/\/doi.org\/10.1002\/pds.4022.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1470_CR13","unstructured":"Organization WH. WHO implementation tool for monitoring the toxicity of new antiretroviral and antiviral medicines in HIV and viral hepatitis programmes. Accessed December 10, 2023. https:\/\/iris.who.int\/handle\/10665\/273053"},{"key":"1470_CR14","unstructured":"Organization WH. Surveillance of antiretroviral toxicity: global HIV, hepatitis and STIs programme: what's new in person-centred HIV patient and antiretroviral drug toxicity monitoring: technical brief. Accessed December 10, 2023. https:\/\/iris.who.int\/handle\/10665\/333000"},{"issue":"5","key":"1470_CR15","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/pds.3739","volume":"24","author":"K Star","year":"2015","unstructured":"Star K, Watson S, Sandberg L, Johansson J, Edwards IR. Longitudinal medical records as a complement to routine drug safety signal analysis. Pharmacoepidemiol Drug Saf. 2015;24(5):486\u201394. https:\/\/doi.org\/10.1002\/pds.3739.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7\u20138","key":"1470_CR16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.drudis.2008.12.012","volume":"14","author":"M Hauben","year":"2009","unstructured":"Hauben M, Bate A. Decision support methods for the detection of adverse events in post-marketing data. Drug Discov Today. 2009;14(7\u20138):343\u201357. https:\/\/doi.org\/10.1016\/j.drudis.2008.12.012.","journal-title":"Drug Discov Today"},{"issue":"3","key":"1470_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1007\/s11096-016-0285-6","volume":"38","author":"KS Lao","year":"2016","unstructured":"Lao KS, Chui CS, Man KK, Lau WC, Chan EW, Wong IC. Medication safety research by observational study design. Int J Clin Pharm. 2016;38(3):676\u201384. https:\/\/doi.org\/10.1007\/s11096-016-0285-6.","journal-title":"Int J Clin Pharm"},{"key":"1470_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5715","author":"M Rahman","year":"2023","unstructured":"Rahman M, Dal Pan G, Stein P, et al. When can real-world data generate real-world evidence? Pharmacoepidemiol Drug Saf. 2023. https:\/\/doi.org\/10.1002\/pds.5715.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1470_CR19","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/jcph.2195","volume":"63","author":"SR da Ferreira","year":"2023","unstructured":"da Ferreira SR, Silva AM, Morato M, Ribeiro-Vaz I, Pol\u00f3nia JJ. Embracing uncertainties over the evidence of new oral antivirals for COVID-19: challenges in pharmacoepidemiologic research. J Clin Pharmacol. 2023;63(5):521\u20135. https:\/\/doi.org\/10.1002\/jcph.2195.","journal-title":"J Clin Pharmacol"},{"issue":"8","key":"1470_CR20","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1007\/s40264-014-0194-3","volume":"37","author":"Y-L Huang","year":"2014","unstructured":"Huang Y-L, Moon J, Segal JB. A comparison of active adverse event surveillance systems worldwide. Drug Saf. 2014;37(8):581\u201396. https:\/\/doi.org\/10.1007\/s40264-014-0194-3.","journal-title":"Drug Saf"},{"key":"1470_CR21","doi-asserted-by":"crossref","unstructured":"Chatterjee S, Aparasu RR. Pharmacovigilance to inform drug safety: challenges and opportunities. Encyclopedia of evidence in pharmaceutical public health and health services research in pharmacy. Springer International Publishing; 2020:1-12:chap Chapter 33-1.","DOI":"10.1007\/978-3-030-50247-8_33-1"},{"key":"1470_CR22","volume-title":"Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care","author":"J Akers","year":"2009","unstructured":"Akers J, Aguiar-Ib\u00e1\u00f1ez R, Baba-Akbari A. Systematic reviews: CRD\u2019s guidance for undertaking reviews in health care. Centre for Reviews and Dissemination: University of York; 2009."},{"key":"1470_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1470_CR24","unstructured":"Agency EM. Guideline on Good Pharmacovigilance Practices (GVP) - Annex I - Definitions (Rev 4). 2017. EMA\/876333\/2011 Rev 4. 9 October 2017. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-good-pharmacovigilance-practices-annex-i-definitions-rev-4_en.pdf"},{"key":"1470_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/B978-012373944-5.00178-4","volume-title":"Encyclopedia of microbiology (Third Edition)","author":"E Paintsil","year":"2009","unstructured":"Paintsil E, Cheng Y-C. Antiviral agents. In: Schaechter M, editor. Encyclopedia of microbiology (Third Edition). Academic Press; 2009. p. 223\u201357."},{"key":"1470_CR26","unstructured":"Mehtodology WCCfDS. ATC\/DDD Index 2023. Accessed November 15, 2023. https:\/\/www.whocc.no\/atc_ddd_index\/"},{"key":"1470_CR27","unstructured":"Wells GA, Wells G, Shea B, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Accessed November 15, 2023. https:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"1470_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"2","author":"LA McGuinness","year":"2020","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 2020;2:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.","journal-title":"Res Synth Methods."},{"issue":"9","key":"1470_CR29","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1002\/pds.1793","volume":"18","author":"H Khalili","year":"2009","unstructured":"Khalili H, Dashti-Khavidaki S, Mohraz M, Etghani A, Almasi F. Antiretroviral induced adverse drug reactions in Iranian human immunodeficiency virus positive patients. Pharmacoepidemiol Drug Saf. 2009;18(9):848\u201357. https:\/\/doi.org\/10.1002\/pds.1793.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1470_CR30","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1002\/pds.1907","volume":"19","author":"RR Modayil","year":"2010","unstructured":"Modayil RR, Harugeri A, Parthasarathi G, et al. Adverse drug reactions to antiretroviral therapy (ART): an experience of spontaneous reporting and intensive monitoring from ART centre in India. Pharmacoepidemiol Drug Saf. 2010;19(3):247\u201355. https:\/\/doi.org\/10.1002\/pds.1907.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"1470_CR31","doi-asserted-by":"publisher","first-page":"245","DOI":"10.4103\/0019-5359.99597","volume":"64","author":"M Nagpal","year":"2010","unstructured":"Nagpal M, Tayal V, Kumar S, Gupta U. Adverse drug reactions to antiretroviral therapy in aids patients at a tertiary care hospital in India: a prospective observational study. Indian J Med Sci. 2010;64(6):245\u201352. https:\/\/doi.org\/10.4103\/0019-5359.99597.","journal-title":"Indian J Med Sci"},{"issue":"2","key":"1470_CR32","first-page":"107","volume":"50","author":"SG Abaissa","year":"2012","unstructured":"Abaissa SG, Fekade D, Feleke Y, Seboxa T, Diro E. Adverse drug reactions associated with antiretroviral treatment among adult Ethiopian patients in a tertiary hospital. Ethiop Med J. 2012;50(2):107\u201313.","journal-title":"Ethiop Med J"},{"issue":"5","key":"1470_CR33","doi-asserted-by":"publisher","first-page":"507","DOI":"10.4067\/S0716-10182013000500007","volume":"30","author":"F Bernal","year":"2013","unstructured":"Bernal F, Vasquez P, Giadalah C, Rodriguez L, Villagran A. Incidence of adverse drug reactions in patients initiating or changing antiretroviral therapy. Rev Chilena Infectol. 2013;30(5):507\u201312. https:\/\/doi.org\/10.4067\/S0716-10182013000500007.","journal-title":"Rev Chilena Infectol"},{"issue":"7","key":"1470_CR34","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s40264-015-0295-7","volume":"38","author":"WM Bezabhe","year":"2015","unstructured":"Bezabhe WM, Bereznicki LR, Chalmers L, et al. Adverse drug reactions and clinical outcomes in patients initiated on antiretroviral therapy: a prospective cohort study from Ethiopia. Drug Saf. 2015;38(7):629\u201339. https:\/\/doi.org\/10.1007\/s40264-015-0295-7.","journal-title":"Drug Saf"},{"issue":"1","key":"1470_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/2229-3485.148808","volume":"6","author":"AK Jha","year":"2015","unstructured":"Jha AK, Gadgade A, Shenoy AK, Chowta MN, Ramapuram JT. Evaluation of adverse drug reactions in HIV positive patients in a tertiary care hospital. Perspect Clin Res. 2015;6(1):34\u20138. https:\/\/doi.org\/10.4103\/2229-3485.148808.","journal-title":"Perspect Clin Res"},{"issue":"27","key":"1470_CR36","doi-asserted-by":"publisher","first-page":"39","DOI":"10.4314\/ejhs.v27i1.5s","volume":"2017\u20132","author":"EK Gudina","year":"2017","unstructured":"Gudina EK, Teklu AM, Berhan A, et al. Magnitude of antiretroviral drug toxicity in adult HIV patients in Ethiopia: a cohort study at seven teaching hospitals. Ethiop J Health Sci. 2017;2017\u20132(27):39\u201352. https:\/\/doi.org\/10.4314\/ejhs.v27i1.5s.","journal-title":"Ethiop J Health Sci"},{"issue":"10","key":"1470_CR37","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1007\/s40267-018-0546-7","volume":"34","author":"AM Isa","year":"2018","unstructured":"Isa AM, Abubakar IJ, Chedi BAZ. Adverse drug reactions to antiretroviral drugs and impact on treatment adherence among HIV patients in northwestern Nigeria. Drugs Therapy Perspect. 2018;34(10):488\u201395. https:\/\/doi.org\/10.1007\/s40267-018-0546-7.","journal-title":"Drugs Therapy Perspect."},{"issue":"5","key":"1470_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.18203\/2319-2003.ijbcp20191565","volume":"8","author":"AA Oumar","year":"2019","unstructured":"Oumar AA, Dakouo M, Tchibozo A, et al. Antiretroviral-induced adverse drug reactions in HIV-infected patients in Mali: a resource-limited setting experience. Int J Basic Clin Pharmacol. 2019;8(5):831\u20136. https:\/\/doi.org\/10.18203\/2319-2003.ijbcp20191565.","journal-title":"Int J Basic Clin Pharmacol"},{"issue":"4","key":"1470_CR39","doi-asserted-by":"publisher","first-page":"596","DOI":"10.33314\/jnhrc.v18i4.2634","volume":"18","author":"DP Sarraf","year":"2020","unstructured":"Sarraf DP, Rauniar GP, Chhetri R, et al. Pharmacovigilance of antiretroviral drugs at B.P. Koirala institute of health sciences. J Nepal Health Res Counc. 2020;18(4):596\u2013603. https:\/\/doi.org\/10.33314\/jnhrc.v18i4.2634.","journal-title":"J Nepal Health Res Counc"},{"issue":"9","key":"1470_CR40","doi-asserted-by":"publisher","first-page":"10","DOI":"10.6000\/1929-6029.2020.09.02","volume":"2020","author":"BO Omolo","year":"2020","unstructured":"Omolo BO, Njuho PM. Adverse event risk assessment on patients receiving combination antiretroviral therapy in South Africa. Int J Stat Med Res. 2020;2020(9):10\u20139. https:\/\/doi.org\/10.6000\/1929-6029.2020.09.02.","journal-title":"Int J Stat Med Res"},{"issue":"3","key":"1470_CR41","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1097\/00126334-200003010-00004","volume":"23","author":"P Bonfanti","year":"2000","unstructured":"Bonfanti P, Valsecchi L, Parazzini F, et al. Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study. J Acquir Immune Defic Syndr. 2000;23(3):236\u201345. https:\/\/doi.org\/10.1097\/00126334-200003010-00004.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"11","key":"1470_CR42","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028112","volume":"6","author":"M Pujades-Rodriguez","year":"2011","unstructured":"Pujades-Rodriguez M, Dantony E, Pinoges L, et al. Toxicity associated with stavudine dose reduction from 40 to 30 mg in first-line antiretroviral therapy. PLoS ONE. 2011;6(11): e28112. https:\/\/doi.org\/10.1371\/journal.pone.0028112.","journal-title":"PLoS ONE"},{"issue":"8","key":"1470_CR43","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1007\/s12325-021-01842-3","volume":"38","author":"H Hongo","year":"2021","unstructured":"Hongo H, Nagao T, Nakamura K, et al. Safety and effectiveness analysis of dolutegravir in patients with HIV-1: interim report of post-marketing surveillance in Japan. Adv Ther. 2021;38(8):4480\u2013504. https:\/\/doi.org\/10.1007\/s12325-021-01842-3.","journal-title":"Adv Ther"},{"issue":"2","key":"1470_CR44","doi-asserted-by":"publisher","first-page":"150","DOI":"10.3947\/ic.2019.51.2.150","volume":"51","author":"H Ann","year":"2019","unstructured":"Ann H, Lee YS, Kim YS, et al. Safety and effectiveness analysis of Kivexa(R) (lamivudine\/abacavir sulfate) in human immunodeficiency virus infected Korean patients. Infect Chemother. 2019;51(2):150\u201360. https:\/\/doi.org\/10.3947\/ic.2019.51.2.150.","journal-title":"Infect Chemother"},{"issue":"3","key":"1470_CR45","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1097\/QAI.0b013e3182423668","volume":"59","author":"VJ Tukei","year":"2012","unstructured":"Tukei VJ, Asiimwe A, et al. Safety and tolerability of antiretroviral therapy among HIV-infected children and adolescents in Uganda. J Acquir Immune Defic Syndr. 2012;59(3):274\u201380. https:\/\/doi.org\/10.1097\/QAI.0b013e3182423668.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"1","key":"1470_CR46","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1186\/s12889-015-1928-6","volume":"15","author":"RA Tetteh","year":"2015","unstructured":"Tetteh RA, Nartey ET, Lartey M, et al. Adverse events and adherence to HIV post-exposure prophylaxis: a cohort study at the Korle-Bu Teaching Hospital in Accra, Ghana. BMC Public Health. 2015;15(1):573. https:\/\/doi.org\/10.1186\/s12889-015-1928-6.","journal-title":"BMC Public Health"},{"issue":"31","key":"1470_CR47","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.14260\/jemds\/2016\/391","volume":"5","author":"AC Joseph","year":"2016","unstructured":"Joseph AC, Sanalkumar KB, Bharathan CS, Andrews MA, Ajithkumar K. Adverse effect profile of tenofovir disoproxil fumarate in hiv positive patients\u2014a prospective study. J Evol Med Dent Sci. 2016;5(31):1659\u201362. https:\/\/doi.org\/10.14260\/jemds\/2016\/391.","journal-title":"J Evol Med Dent Sci"},{"issue":"5","key":"1470_CR48","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/1545109709343967","volume":"8","author":"A Jena","year":"2009","unstructured":"Jena A, Sachdeva RK, Sharma A, Wanchu A. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study. J Int Assoc Physicians AIDS Care. 2009;8(5):318\u201322. https:\/\/doi.org\/10.1177\/1545109709343967.","journal-title":"J Int Assoc Physicians AIDS Care"},{"issue":"3","key":"1470_CR49","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4103\/0378-6323.41368","volume":"74","author":"A Sharma","year":"2008","unstructured":"Sharma A, Vora R, Modi M, Sharma A, Marfatia Y. Adverse effects of antiretroviral treatment. Indian J Dermatol Venereol Leprol. 2008;74(3):234\u20137. https:\/\/doi.org\/10.4103\/0378-6323.41368.","journal-title":"Indian J Dermatol Venereol Leprol"},{"issue":"11","key":"1470_CR50","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jiac.2014.07.006","volume":"20","author":"T Komeda","year":"2014","unstructured":"Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigation. J Infect Chemother. 2014;20(11):689\u201395. https:\/\/doi.org\/10.1016\/j.jiac.2014.07.006.","journal-title":"J Infect Chemother"},{"issue":"3","key":"1470_CR51","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jiac.2014.11.009","volume":"21","author":"T Komeda","year":"2015","unstructured":"Komeda T, Ishii S, Itoh Y, et al. Post-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir. II: a pediatric drug use investigation. J Infect Chemother. 2015;21(3):194\u2013201. https:\/\/doi.org\/10.1016\/j.jiac.2014.11.009.","journal-title":"J Infect Chemother"},{"issue":"10","key":"1470_CR52","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jiac.2016.07.004","volume":"22","author":"T Komeda","year":"2016","unstructured":"Komeda T, Ishii S, Itoh Y, Sanekata M, Yoshikawa T, Shimada J. Post-marketing safety evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir: a drug-use investigation in patients with high risk factors. J Infect Chemother. 2016;22(10):677\u201384. https:\/\/doi.org\/10.1016\/j.jiac.2016.07.004.","journal-title":"J Infect Chemother"},{"issue":"5","key":"1470_CR53","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.ijantimicag.2012.06.017","volume":"40","author":"S Kashiwagi","year":"2012","unstructured":"Kashiwagi S, Yoshida S, Yamaguchi H, et al. Safety of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate in post-marketing surveillance. Int J Antimicrob Agents. 2012;40(5):381\u20138. https:\/\/doi.org\/10.1016\/j.ijantimicag.2012.06.017.","journal-title":"Int J Antimicrob Agents"},{"issue":"10","key":"1470_CR54","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.jiac.2021.06.004","volume":"27","author":"T Nakano","year":"2021","unstructured":"Nakano T, Yamaguchi H, Chiba T, Shiosakai K, Chikada S, Matsuoka Y. The safety and efficacy of the long-acting neuraminidase inhibitor laninamivir octanoate hydrate for Inhalation Suspension Set in children under the age of 5 in a post-marketing surveillance. J Infect Chemother. 2021;27(10):1436\u201346. https:\/\/doi.org\/10.1016\/j.jiac.2021.06.004.","journal-title":"J Infect Chemother"},{"issue":"2","key":"1470_CR55","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.81901","volume":"2","author":"PS Dalvi","year":"2011","unstructured":"Dalvi PS, Singh A, Trivedi HR, Mistry SD, Vyas BR. Adverse drug reaction profile of oseltamivir in children. J Pharmacol Pharmacother. 2011;2(2):100\u20133. https:\/\/doi.org\/10.4103\/0976-500X.81901.","journal-title":"J Pharmacol Pharmacother"},{"issue":"2","key":"1470_CR56","doi-asserted-by":"publisher","first-page":"071","DOI":"10.3233\/jpi-130381","volume":"8","author":"T Tahara","year":"2013","unstructured":"Tahara T, Asano Y, Mitamura K, Nakamura H, Itoh S. Safety of oseltamivir in infants less than one year old: Prospective surveillance during the 2004\u20132005 influenza season in Japan. J Pediatr Infect Dis. 2013;8(2):071\u201381. https:\/\/doi.org\/10.3233\/jpi-130381.","journal-title":"J Pediatr Infect Dis"},{"issue":"7","key":"1470_CR57","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jiac.2020.04.014","volume":"26","author":"M Nakazawa","year":"2020","unstructured":"Nakazawa M, Hara K, Komeda T, Ogura E. Safety and effectiveness of baloxavir marboxil for the treatment of influenza in Japanese clinical practice: a postmarketing surveillance of more than 3000 patients. J Infect Chemother. 2020;26(7):729\u201335. https:\/\/doi.org\/10.1016\/j.jiac.2020.04.014.","journal-title":"J Infect Chemother"},{"issue":"11","key":"1470_CR58","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pds.2025","volume":"19","author":"F Tin\u00e8","year":"2010","unstructured":"Tin\u00e8 F, Graviano D, Giannuoli G, et al. An open-safety study of dual antiviral therapy in real-world patients with chronic hepatitis C. Pharmacoepidemiol Drug Saf. 2010;19(11):1113\u201323. https:\/\/doi.org\/10.1002\/pds.2025.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"1470_CR59","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1007\/s12072-018-9872-z","volume":"12","author":"F Suzuki","year":"2018","unstructured":"Suzuki F, Hatanaka N, Nakamura K, Komoto A. Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan. Hepatol Int. 2018;12(3):244\u201353. https:\/\/doi.org\/10.1007\/s12072-018-9872-z.","journal-title":"Hepatol Int"},{"issue":"3","key":"1470_CR60","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/1574886313666180716111529","volume":"13","author":"EI Ahmed","year":"2018","unstructured":"Ahmed EI, Wahed WYA, Hassan EA, Ahmed TI. Study of adverse drug effects of direct-acting antivirals for chronic HCV infection at fayoum governorate, Egypt\u2014a pharmacovigilance study. Curr Drug Saf. 2018;13(3):187\u201395. https:\/\/doi.org\/10.2174\/1574886313666180716111529.","journal-title":"Curr Drug Saf"},{"issue":"1","key":"1470_CR61","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/jvh.13395","volume":"28","author":"M Mizokami","year":"2021","unstructured":"Mizokami M, Liu LJ, Fujiyama N, et al. Real-world safety and effectiveness of ledipasvir\/sofosbuvir for the treatment of chronic hepatitis C virus genotype 1 in Japan. J Viral Hepat. 2021;28(1):129\u201341. https:\/\/doi.org\/10.1111\/jvh.13395.","journal-title":"J Viral Hepat"},{"issue":"1","key":"1470_CR62","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3904\/kjim.2016.111","volume":"33","author":"CW Kim","year":"2018","unstructured":"Kim CW, Kim CS, Kim HY, et al. Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. Korean J Intern Med. 2018;33(1):91\u2013101. https:\/\/doi.org\/10.3904\/kjim.2016.111.","journal-title":"Korean J Intern Med"},{"issue":"6","key":"1470_CR63","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1136\/jamia.2010.008607","volume":"17","author":"PM Nadkarni","year":"2010","unstructured":"Nadkarni PM. Drug safety surveillance using de-identified EMR and claims data: issues and challenges. J Am Med Inform Assoc. 2010;17(6):671\u20134. https:\/\/doi.org\/10.1136\/jamia.2010.008607.","journal-title":"J Am Med Inform Assoc"},{"issue":"12","key":"1470_CR64","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/pds.1668","volume":"17","author":"R Platt","year":"2008","unstructured":"Platt R, Madre L, Reynolds R, Tilson H. Active drug safety surveillance: a tool to improve public health. Pharmacoepidemiol Drug Saf. 2008;17(12):1175\u201382. https:\/\/doi.org\/10.1002\/pds.1668.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"1470_CR65","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.cgh.2018.09.041","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Younossi I, et al. Long-term effects of treatment for chronic HBV infection on patient-reported outcomes. Clin Gastroenterol Hepatol. 2019;17(8):1641-1642.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.09.041.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"1470_CR66","doi-asserted-by":"publisher","first-page":"S7","DOI":"10.1097\/01.aids.0000327510.68503.e8","volume":"22","author":"TC Quinn","year":"2008","unstructured":"Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008;22(3):S7-12. https:\/\/doi.org\/10.1097\/01.aids.0000327510.68503.e8.","journal-title":"AIDS"},{"issue":"2","key":"1470_CR67","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/(sici)1099-1557(199803\/04)7:2<79::Aid-pds330>3.0.Co;2-1","volume":"7","author":"DM Coulter","year":"1998","unstructured":"Coulter DM. The New Zealand Intensive Medicines Monitoring Programme. Pharmacoepidemiol Drug Saf. 1998;7(2):79\u201390. https:\/\/doi.org\/10.1002\/(sici)1099-1557(199803\/04)7:2%3c79::Aid-pds330%3e3.0.Co;2-1.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6271","key":"1470_CR68","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1136\/bmj.282.6271.1216","volume":"282","author":"WH Inman","year":"1981","unstructured":"Inman WH. Postmarketing surveillance of adverse drug reactions in general practice. II: Prescription-event monitoring at the University of Southampton. Br Med J. 1981;282(6271):1216\u20137. https:\/\/doi.org\/10.1136\/bmj.282.6271.1216.","journal-title":"Br Med J"},{"issue":"6344","key":"1470_CR69","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1136\/bmj.285.6344.809-b","volume":"285","author":"WH Inman","year":"1982","unstructured":"Inman WH. Prescription-event monitoring. Br Med J (Clin Res Ed). 1982;285(6344):809\u201310. https:\/\/doi.org\/10.1136\/bmj.285.6344.809-b.","journal-title":"Br Med J (Clin Res Ed)"},{"issue":"1","key":"1470_CR70","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1002\/pds.773","volume":"12","author":"PC Waller","year":"2003","unstructured":"Waller PC, Evans SJ. A model for the future conduct of pharmacovigilance. Pharmacoepidemiol Drug Saf. 2003;12(1):17\u201329. https:\/\/doi.org\/10.1002\/pds.773.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"1470_CR71","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11593830-000000000-00000","volume":"34","author":"D Layton","year":"2011","unstructured":"Layton D, Hazell L, Shakir SA. Modified prescription-event monitoring studies: a tool for pharmacovigilance and risk management. Drug Saf. 2011;34(12):e1-9. https:\/\/doi.org\/10.2165\/11593830-000000000-00000.","journal-title":"Drug Saf"},{"issue":"11","key":"1470_CR72","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1007\/s002280000232","volume":"56","author":"K Kubota","year":"2001","unstructured":"Kubota K, Kawabe E, Hinotsu S, Hamada C, Ohashi Y, Kurokawa K. Pilot study of prescription-event monitoring in Japan comparing troglitazone with alternative oral hypoglycemics. Eur J Clin Pharmacol. 2001;56(11):831\u20138. https:\/\/doi.org\/10.1007\/s002280000232.","journal-title":"Eur J Clin Pharmacol"},{"key":"1470_CR73","doi-asserted-by":"publisher","first-page":"875","DOI":"10.3389\/fphar.2018.00875","volume":"9","author":"L Wang","year":"2018","unstructured":"Wang L, Rastegar-Mojarad M, Ji Z, et al. Detecting pharmacovigilance signals combining electronic medical records with spontaneous reports: a case study of conventional disease-modifying antirheumatic drugs for rheumatoid arthritis. Front Pharmacol. 2018;9:875. https:\/\/doi.org\/10.3389\/fphar.2018.00875.","journal-title":"Front Pharmacol"},{"issue":"6","key":"1470_CR74","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1002\/(SICI)1099-1557(199910\/11)8:6<447::AID-PDS446>3.0.CO;2-I","volume":"8","author":"K Kubota","year":"1999","unstructured":"Kubota K. A design for prescription-event monitoring in Japan (J-PEM). Pharmacoepidemiol Drug Saf. 1999;8(6):447\u201356. https:\/\/doi.org\/10.1002\/(SICI)1099-1557(199910\/11)8:6%3c447::AID-PDS446%3e3.0.CO;2-I.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"1470_CR75","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-020-01007-1","volume":"44","author":"A Simbrich","year":"2021","unstructured":"Simbrich A, Thibaut J, Khil L, Maximov S, Wiendl H, Berger K. Chances and challenges of registry-based pharmacovigilance in multiple sclerosis: lessons learnt from the implementation of the multicenter REGIMS registry. Drug Saf. 2021;44(1):7\u201315. https:\/\/doi.org\/10.1007\/s40264-020-01007-1.","journal-title":"Drug Saf"},{"issue":"2","key":"1470_CR76","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1002\/pds.4150","volume":"26","author":"K Gelperin","year":"2017","unstructured":"Gelperin K, Hammad H, Leishear K, et al. A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. Pharmacoepidemiol Drug Saf. 2017;26(2):208\u201314. https:\/\/doi.org\/10.1002\/pds.4150.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"1470_CR77","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/s41433-021-01897-0","volume":"36","author":"A Miroshnychenko","year":"2022","unstructured":"Miroshnychenko A, Zeraatkar D, Phillips MR, et al. Cohort studies investigating the effects of exposures: key principles that impact the credibility of the results. Eye. 2022;36(5):905\u20136. https:\/\/doi.org\/10.1038\/s41433-021-01897-0.","journal-title":"Eye"},{"key":"1470_CR78","unstructured":"Agency EM. Patient registries. Accessed December 12, 2023. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/patient-registries"},{"issue":"6653","key":"1470_CR79","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1136\/bmj.297.6653.891","volume":"297","author":"AS Mitchell","year":"1988","unstructured":"Mitchell AS, Henry DA, Sanson-Fisher R, O\u2019Connell DL. Patients as a direct source of information on adverse drug reactions. BMJ. 1988;297(6653):891\u20133. https:\/\/doi.org\/10.1136\/bmj.297.6653.891.","journal-title":"BMJ"},{"key":"1470_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph19010413","volume":"19","author":"K Sienkiewicz","year":"2021","unstructured":"Sienkiewicz K, Burzy\u0144ska M, Rydlewska-Liszkowska I, Sienkiewicz J, Gaszy\u0144ska E. The importance of direct patient reporting of adverse drug reactions in the safety monitoring process. Int J Environ Res Public Health. 2021;19:1. https:\/\/doi.org\/10.3390\/ijerph19010413.","journal-title":"Int J Environ Res Public Health"},{"key":"1470_CR81","unstructured":"Organization WH. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Accessed December 11, 2023. https:\/\/www.who.int\/publications\/i\/item\/9789240031593"},{"issue":"3","key":"1470_CR82","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/amiajnl-2012-001119","volume":"20","author":"M Liu","year":"2013","unstructured":"Liu M, McPeek Hinz ER, Matheny ME, et al. Comparative analysis of pharmacovigilance methods in the detection of adverse drug reactions using electronic medical records. J Am Med Inform Assoc. 2013;20(3):420\u20136. https:\/\/doi.org\/10.1136\/amiajnl-2012-001119.","journal-title":"J Am Med Inform Assoc"},{"issue":"4","key":"1470_CR83","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1093\/jamia\/ocw168","volume":"24","author":"S Lee","year":"2017","unstructured":"Lee S, Choi J, Kim HS, et al. Standard-based comprehensive detection of adverse drug reaction signals from nursing statements and laboratory results in electronic health records. J Am Med Inform Assoc. 2017;24(4):697\u2013708. https:\/\/doi.org\/10.1093\/jamia\/ocw168.","journal-title":"J Am Med Inform Assoc"},{"key":"1470_CR84","doi-asserted-by":"publisher","DOI":"10.1002\/9781118820186","volume-title":"Mann's pharmacovigilance","author":"EB Andrews","year":"2014","unstructured":"Andrews EB, Moore N. Mann\u2019s pharmacovigilance. New York: Wiley; 2014."},{"issue":"1","key":"1470_CR85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.2174\/1872208314666201021162704","volume":"15","author":"MV Satwika","year":"2021","unstructured":"Satwika MV, Sushma DS, Jaiswal V, Asha S, Pal T. The role of advanced technologies supplemented with traditional methods in pharmacovigilance sciences. Recent Pat Biotechnol. 2021;15(1):34\u201350. https:\/\/doi.org\/10.2174\/1872208314666201021162704.","journal-title":"Recent Pat Biotechnol"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-024-01470-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-024-01470-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T02:15:07Z","timestamp":1731377707000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-024-01470-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,19]]},"references-count":85,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["1470"],"URL":"https:\/\/doi.org\/10.1007\/s40264-024-01470-0","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,19]]},"assertion":[{"value":"17 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Renato Ferreira da Silva is grateful for the PhD scholarship 2020.10231.BD (DOCTORATES 4 COVID-19), funded by Portuguese national funds and community funds from the European Social Fund (ESF) through FCT \u2013 <i>Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia<\/i> (Portugal). The Porto Pharmacovigilance Centre is a regional centre of the Portuguese Pharmacovigilance System, funded by INFARMED \u2013 National Authority for Medicines and Health Products of Portugal, I.P.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This article includes a review of studies involving human participants. However, as the review does not contain identifiable information and relies on previously published data, it is exempt from ethical approval.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"All data generated and analysed during this study are included in this published article (and its electronic supplementary material).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"The authors declare that they have no conflicts of interest that could potentially influence the work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The online form used for data extraction was created internally and is not publicly available. Upon reasonable request, the form can be provided by the corresponding author.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"R.F.S. wrote the manuscript; R.F.S., M.M.S., M.M., J.J.P., and I.R.V. designed the research; R.F.S., J.R.P., M.P. performed the research; R.F.S., R.F.S., J.R.P., M.P., M.M.S., B.S.P., M.M., J.J.P., and I.R.V. analysed the data. All authors read and approved the final version of the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}